Ionis earns $40M on Spinraza advance; Five Prime axes Inhibrx deal
⇨ Ionis is picking up another big check from Biogen related to the rollout of Spinraza. The biotech $IONS garnered $40 million on approval of the price in Japan, bringing its total take to $435 million.
⇨ Five Prime Therapeutics is punting its $452 million research pact — which came with a $10 million upfront — with Inhibrx. The biotech axed the deal two days ago, according to an SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.